Today: 20 December 2025
Subscribe
Browse Category

NYSE:LLY News 11 December 2025 - 18 December 2025

Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly and Company (NYSE: LLY) finished Thursday’s session higher and held those gains in after-hours trading, as investors digested fresh late-stage data for its oral obesity candidate orforglipron—and weighed a second, potentially market-moving theme: pricing pressure and affordability initiatives.
18 December 2025
 ·  ·  ·  ·  ·  · 
Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025

Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025

December 15, 2025 — Eli Lilly and Company (NYSE: LLY) stock is starting the new week in focus as investors weigh a rapid-fire set of catalysts: a headline-grabbing Phase 3 result for next‑generation obesity drug retatrutide, fresh scrutiny around the
15 December 2025
 ·  ·  ·  ·  · 
Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025)

Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025)

Updated: December 14, 2025 Eli Lilly and Company (NYSE: LLY) heads into the new week with investors focused on one big theme: how far the company can extend its lead in obesity and cardiometabolic medicine while scaling supply and navigating
14 December 2025
 ·  ·  ·  ·  · 
Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Updated: December 12, 2025Company: Eli Lilly and Company (NYSE: LLY)Stock price (last close):$1,027.51 MarketWatch Eli Lilly stock closed the week at $1,027.51 after a late-week rally, outperforming a softer broader market session on Friday. MarketWatch The catalyst mix was familiar—but
13 December 2025
 ·  ·  ·  ·  · 
Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly and Company shares ended Friday, Dec. 12, 2025 higher — and held roughly steady in after-hours trading — as investors weighed a fresh European regulatory boost for Mounjaro, new reporting on the FDA’s internal debate over speeding up
12 December 2025
 ·  ·  ·  ·  · 
Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly (LLY) stock is moving as investors weigh standout retatrutide Phase 3 results, a Reuters report on FDA review timing for orforglipron, and updated Wall Street price targets. Published: December 12, 2025 Eli Lilly and Company stock (NYSE: LLY)
12 December 2025
 ·  ·  ·  ·  · 
Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly and Company (NYSE: LLY) ended Thursday’s session back near record territory as Wall Street digested stunning new weight‑loss data from its experimental obesity drug retatrutide, a massive new U.S. manufacturing investment, and fresh signs of global expansion for
11 December 2025
 ·  ·  ·  ·  · 
Best Stocks to Buy Now in the U.S. Stock Market (December 11, 2025)

Best Stocks to Buy Now in the U.S. Stock Market (December 11, 2025)

The U.S. stock market is ending 2025 near record highs, but today’s tape is choppy: a fresh Federal Reserve rate cut is colliding with worries that AI spending is turning into a bubble. Reuters+1 Against that backdrop, investors are asking
11 December 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Eli Lilly (LLY) After Hours: How a $6 Billion Bet, Fresh Oncology Data and Fed Rate Cut Set the Stage for December 11, 2025

Eli Lilly (LLY) After Hours: How a $6 Billion Bet, Fresh Oncology Data and Fed Rate Cut Set the Stage for December 11, 2025

Eli Lilly and Company (NYSE: LLY) closed just under the psychologically important $1,000 mark on Wednesday, December 10, 2025, then ticked slightly higher in after‑hours trading as investors digested a wave of company‑specific news against a backdrop of a fresh
11 December 2025
 ·  ·  ·  ·  · 
1 2 3 … 6
Go toTop